Severe renal impairment during triple therapy with telaprevir

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 4, 2014, Pages e69-e71

  Carrier, P ^a   Chambaraud, T ^a   Vong, C ^b   Guillaudeau, A ^a   Debette Gratien, M ^a   Jacques, J ^a   Legros, R ^a   Sautereau, D ^a   Essig, M ^a,b   Loustaud Ratti, V ^a,c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b Univ Limoges   (France)

^c UMR 1092   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEVOTHYROXINE; PARACETAMOL; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ANTIVIRAL THERAPY; BLOOD TRANSFUSION; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; ELASTOGRAPH; FEMALE; FIBROSING ALVEOLITIS; HEPATITIS C; HUMAN; HYPERTHYROIDISM; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; LETTER; LEUKOCYTURIA; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; PROTEINURIA; RELAPSE; THALASSEMIA MINOR; THYROIDECTOMY; TREATMENT DURATION; CHEMICALLY INDUCED; SEVERITY OF ILLNESS INDEX;

ACUTE KIDNEY INJURY; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 84912529478     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.12.005     Document Type: Letter

References (9)

1. Loustaud-Ratti V., Carrier P., Vong C., et al. Reply to: renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2013, [Epub ahead of print]. 10.1002/hep.26730.
2. Russo M.W., Fried M.W. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124:1711-1719.
3. Shah M., Jenis E.H., Mookerjee B.K., et al. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1998, 83:1938-1946.
4. Jadoul M., Piessevaux H., Ferrant A., et al. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant 1995, 10:111-113.
5. Willson R.A. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002, 35:89-92.
6. Fahal I.H., Murry N., Chu P., et al. Acute renal failure during interferon treatment. BMJ 1993, 306:973.
7. Hézode C., Fontaine H., Dorival C., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC). J Hepatol 2013, 59:434-441.
8. Mauss S., Hueppe D., Alshut U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2013, [Epub ahead of print]. 10.1002/hep.26602.
9. Kunze A., Huwyler J., Camenisch G., et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012, 84:1096-1102.